Also in a wt p53 context, treatment of castrate resistant prostate cancer has been proposed using the combination of a small molecule inhibitor of MDM4 expression (NSC207895) and a MDM2 inhibitor (Nutlin-3). Here, TP53 is linked to prostate cancer.